Phase I Study of Intratumoral Administration of HF10, Oncolytic Herpes Simplex Virus Type 1, in Patients with Advanced Unresectable Pancreatic Cancer

Phase I Study of Intratumoral Administration of HF10, Oncolytic Herpes Simplex Virus Type 1, in Patients with Advanced Unresectable Pancreatic Cancer - Clinical Study using HF10 against Advanced Unresectable Pancreatic Cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010150

Enrollment

Registered

2013-03-04

Start date

2013-04-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Unresectable Pancreatic Cancer

Interventions

Drug : HF10 Dose/cohort : Cohort1 : 1x10(6) pfu/day Cohort2 : 3x10(6) pfu/day Cohort3 : 1x10(7) pfu/day Method : 1 injection/2 weeks. Total 4 injections in combination with Erlotinib and Gemci

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Non-resectable locally advanced pancreatic cancer. -Tumor lesion accessible by EUS. -No systemic metastasis. (PL invasion to be included in the locally advanced cancer.)

Exclusion criteria

Exclusion criteria: Patient with: -Ascites. pleural infusion. -Infectious disease. -Any other cancer. -Brain metastasis. -hypersensitivity to live-virus vaccine. Pregnant or breast feeding patient.

Design outcomes

Primary

Measure	Time frame
Safety and tolerability	—

Secondary

Measure	Time frame
anti-tumor activity Immune response Viral replication	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026